Project 2: Coordinate regulation of liver energy balance by PPARalpha/SRC-1 and FXR/SRC-2
项目2:PPARα/SRC-1和FXR/SRC-2协调调节肝脏能量平衡
基本信息
- 批准号:10153761
- 负责人:
- 金额:$ 35.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-01 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:Adipose tissueAgonistAlbuminsAutophagocytosisBile AcidsBindingBlood Coagulation FactorBrainCarbohydratesComplementComplexDrug usageEnterohepatic CirculationFamilyFastingFatty AcidsFibratesGenesGenetic TranscriptionGluconeogenesisGoalsHepaticHepatocyteHomebound PersonsHomeostasisHumanIn VitroIndividualKnockout MiceLigandsLipidsLiverMass Spectrum AnalysisMediatingMediator of activation proteinMetabolicMetabolic PathwayMetabolic syndromeMetabolismMonkeysMusNuclear ReceptorsNutrientOutputPPAR alphaPathway interactionsPharmaceutical PreparationsProductionProteinsProteomicsRXRRegulationRepressionResponse ElementsRoleSerumSiteStructureSystemTestingTherapeutic EffectTranscription CoactivatorTranscription Repressorabsorptionbasecholestatic liver diseaseenergy balancefatty acid oxidationfeedinggenome-wideglucose uptakein vivoinsightlipid biosynthesisliver functionmembermetabolomicsnuclear receptor coactivator 1programsreceptorrecruitresponsetranscriptomics
项目摘要
Project 2 - Project Summary
The primary goal of this project is to elucidate the roles of the nuclear receptors PPARα and FXR, and the
coregulators SRC-1 and SRC-2, in the overall control of energy balance in the liver. PPARα is activated in the
fasted state, promoting fatty acid oxidation and gluconeogenesis. FXR is activated in the fed state and represses
gluconeogenesis. Transcriptional functions of PPARα and FXR are mediated by the SRC family of coactivators,
and the members of this Program Project team have shown that SRC-1 and SRC-2 are also central regulators
of liver energy balance. SRC-2 promotes hepatic fed state functions, including glucose uptake and lipid
absorption, and SRC-2 activity is inhibited in the fasted state. In contrast, SRC-1 is induced by fasting and is
essential for activation of gluconeogenesis in the fasted state. We have recently shown that PPARα and FXR
coordinately regulate another fundamental nutrient response in the liver, autophagy, via mutually antagonistic
effects of induction and repression. Our preliminary results identify the hepatic secretome as another, quite
unexpected potential target for complementary control of liver energy balance. Secretion is a very energy
intensive function of the liver, and we have evidence that FXR activates the hepatic secretome, while PPARα
represses it. Based on these results, our overall hypothesis is that PPARα, in concert with SRC-1, and FXR, in
concert with SRC-2, regulate broad pathways of energy utilization and production in the liver to maintain energy
balance. We propose 3 aims to critically test this hypothesis and explore the mechanistic basis for these effects.
1. Complete the genome wide cistromic, transcriptomic, proteomic and metabolomic profiling of the roles of
PPARα and FXR in the fed and fasted liver. 2. Define the role of SRC-1, SRC-2 and NCoR in the opposing
effects of PPARα and FXR in vivo. 3. Define the structural and functional basis for the conversion of FXR/RXR
heterodimers from ligand dependent transcriptional activators on IR-1 sites to ligand dependent transcriptional
repressors on DR-1 sites, and define the coregulators associated with both.
项目2-项目摘要
该项目的主要目标是阐明核接收器PPARα和FXR的作用,以及
COREGULATORS SRC-1和SRC-2在肝脏能量平衡的总体控制中。 PPARα在
禁食状态,促进脂肪酸氧化和糖异生。 FXR在美联储状态中被激活,并反映
谷氨酸生成。 PPARα和FXR的转录函数是由SRC共激活因子家族介导的,
该计划项目团队的成员表明,SRC-1和SRC-2也是中央监管机构
肝脏能量平衡。 SRC-2促进肝脏喂养状态功能,包括葡萄糖摄取和脂质
在禁食状态下抑制抽象和SRC-2活性。相反,SRC-1是由禁食诱导的,IS
在禁食状态下激活糖异生必不可少的。我们最近表明PPARα和FXR
通过相互拮抗作用,协调调节肝脏自噬中的另一种基本营养反应
诱导和反射的影响。我们的初步结果将肝脏分泌组确定为另一个
完全控制肝能量平衡的意外潜在目标。分泌是一种能量
肝脏的密集功能,我们有证据表明FXR激活肝分泌组,而PPARα
压抑它。基于这些结果,我们的总体假设是,PPARα与SRC-1和FXR一致
与SRC-2合作,调节肝脏中能量利用和生产的广泛途径以维持能量
平衡。我们提出3个旨在批判性检验这一假设并探索这些效果的机械基础的目的。
1。完成基因组宽性毛虫,转录组,蛋白质组学和代谢组分析的作用
美联储和禁食的肝脏中的PPARα和FXR。 2。定义SRC-1,SRC-2和NCOR在相对中的作用
PPARα和FXR在体内的影响。 3。定义fxr/rxr转换的结构和功能性巴西
来自IR-1位点上配体依赖性转录激活剂的异二聚体到配体依赖性转录
DR-1站点上的阻遏物,并定义与两者相关的核心节目。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID D MOORE其他文献
DAVID D MOORE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID D MOORE', 18)}}的其他基金
Project 2: Coordinate regulation of liver energy balance by PPARalpha/SRC-1 and FXR/SRC-2
项目2:PPARα/SRC-1和FXR/SRC-2协调调节肝脏能量平衡
- 批准号:
10421283 - 财政年份:2018
- 资助金额:
$ 35.66万 - 项目类别:
Metabolic Regulation by the Nuclear Receptor CAR
核受体 CAR 的代谢调节
- 批准号:
7003683 - 财政年份:2003
- 资助金额:
$ 35.66万 - 项目类别:
Metabolic Regulation by the Nuclear Receptor CAR
核受体 CAR 的代谢调节
- 批准号:
6567797 - 财政年份:2003
- 资助金额:
$ 35.66万 - 项目类别:
相似国自然基金
新型IL2Rβγ激动剂逐级控释联合放疗对抗三阴性乳腺癌的作用及机制研究
- 批准号:82303819
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
负载自组装型非核苷类STING激动剂的亚精胺水凝胶用于抗肿瘤免疫治疗及机制研究
- 批准号:82303561
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向SIRT3小分子激动剂调控三阴性乳腺癌细胞自噬和免疫微环境的机制研究
- 批准号:82373193
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于OSMAC-GNPS分析策略的蚂蚱内生真菌Aspergillus sp.中新颖泛PPAR激动剂的发现及治疗NASH研究
- 批准号:82304340
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
探究FSP1激动剂在治疗肾缺血再灌注损伤中的分子机理与应用
- 批准号:82304600
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of Anorexigenic and Glucoregulatory Chimeric Peptides
厌食和血糖调节嵌合肽的开发
- 批准号:
10735323 - 财政年份:2023
- 资助金额:
$ 35.66万 - 项目类别:
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (T1-DISCO)
1 型糖尿病索马鲁肽对心血管结局的影响 (T1-DISCO)
- 批准号:
10672454 - 财政年份:2022
- 资助金额:
$ 35.66万 - 项目类别:
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (T1-DISCO)
1 型糖尿病索马鲁肽对心血管结局的影响 (T1-DISCO)
- 批准号:
10507929 - 财政年份:2022
- 资助金额:
$ 35.66万 - 项目类别:
Project 2: Coordinate regulation of liver energy balance by PPARalpha/SRC-1 and FXR/SRC-2
项目2:PPARα/SRC-1和FXR/SRC-2协调调节肝脏能量平衡
- 批准号:
10421283 - 财政年份:2018
- 资助金额:
$ 35.66万 - 项目类别: